Sigillins from Springtails Are Potent Natural Insecticides.

Sigillins are highly chlorinated natural products from the springtail Ceratophysella sigillata (Collembola) that are used to deter arthropod predators. We report here the isolation and structure elucidation of sigillin F, a hydrogenated benzopyranone compound bearing two trichloromethyl groups, and the synthesis of trideoxysigillin (8), a non-natural compound representing the basic scaffold of the sigillins. Sigillins A and F showed insecticidal activity toward various insects, similar to the commercial insecticide imidacloprid, whereas 8 was inactive. The highest mortality was observed for the aphids Megoura viciae and Myzus persicae, but other insect species were also susceptible. Sigillins act as noncompetitive antagonists of the GABA receptor. This mode of action is identical to that of known insecticides with high chlorine content such as dieldrin or endosulfan. The high content of sigillins in C. sigillata, more than 4 mM in concentration, indicates self-resistance. Strikingly, the Collembola and humans have both arrived at the same target with related types of compounds to combat insects.

Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer.

Aliphatic and ethylene glycol esters of 5-aminolevulinic acid (ALA) are very efficient precursors of the photosensitizer protoporphyrin IX (PpIX) for photodynamic therapy; however, they diffuse passively across the cell membrane and thus lack cell selectivity. We evaluated whether alpha-glucose, alpha-mannose, or beta-galactose esters of ALA would present improved properties as precursors of PpIX. Esterification was performed either at the position O-1 or O-6 of the sugars with or without an ethylene glycol linker, and these glycoside esters of ALA were evaluated in human cells. The results demonstrated that glycoside esters of ALA are efficient precursors of PpIX in human cancer and angiogenic endothelial cells, comparable to free ALA, but not in normal human fibroblasts. PpIX production was confirmed by fluorescence microscopy and photodynamic treatment of cells. The O-1 or O-6 positions of functionalization and the nature of the sugar moiety did not influence PpIX production. The presence of the ethylene glycol linker generally resulted in decreased PpIX production. The uptake of these glycoside esters of ALA by cells was not decreased in the presence of high concentrations of the related sugars. Inhibitors of alpha-glucosidases or alpha-mannosidases did not decrease PpIX production. These results suggest the involvement of active non-glycoside-specific membrane transporter(s) for uptake and of esterases rather than glycosidases in the release of ALA from the glycoside esters of ALA.

Novel bioconjugates of aminolevulinic acid with vitamins.

5-Aminolevulinic acid (ALA) and derivatives thereof have been successfully used in photodynamic cancer therapy (PDT). The synthesis of novel bioconjugates combining ALA with two lipophilic and one hydrophilic vitamins is reported. The new bioconjugates allow studying the potential synergies between the two components in PDT. The synthetic methodology is robust giving the bioconjugates in good to satisfactory yield.

Facile synthesis of a "ready to use" precursor of porphobilinogen and its amino Acid derivatives.

A practical synthesis of porphobilinogen based on the biosynthetic mechanism is described. The crossed Mukayiama aldol reaction is the key step creating the central carbon-carbon bond between the two protected forms of 5-aminolevulinic acids. The optimized sequence gives a crystalline, storable precursor, which can be transformed in high yield into porphobilinogen and bioconjugates thereof. The enzymatic hydrolysis of the precursor produces porphobilinogen in quantitative yield.